Obeticholic Acid CAS#1516887-33-4

Message

$25.00

Have chosenThere are no options selected.

Start To Order

Add To Cart Successfully!

SEND INQUIRY
Obeticholic Acid CAS#1516887-33-4

Obeticholic Acid CAS#1516887-33-4

  • Item No. API
    MOQ 10 Gram
Tag   sourcing
Add Request About This Product
Max file 5MB each
If lager file please send us email

Quantity:

From $ 25.0010.00  / Gram
$ 250.00
You save  $  -250.00
Trade Assurance protects your orders
On-time Dispatch Guarantee
On-time dispatch is guaranteed or you will be eligible to claim platform compensation.
Refund Policy
If the shipment is delayed or product quality differs from what are specified in the online order, you can claim for a refund.
Quick refund: If you can apply for a refund within two hours of making a payment, you will receive a refund immediately.

If you have your own design, please contact us, there will have a professional customer service to communicate with you.

Don't have your files right now?No worries, Check out our art tips for more information.

If over 500pcs, mass production will start until pre-production sample has been approved.

Est. 7 days production

 Obeticholic Acid CAS#1516887-33-4

 

Introduction

 

Obeticholic acid (Obeticholic Acid), also known as 6-ethyl chenodeoxycholic acid, is a new derivative of chenodeoxycholic acid (CDCA) in the primary bile acid, and a natural ligand for the farneside derivatives X receptor ( FXR). Oberbetaine is an agonist for farnesol X receptor, inhibiting gene expression of cytochrome 7A1 (CYP7A1) by activating the farnesol X receptor. Because CYP7A1 is the rate-limiting enzyme for biosynthesis of cholic acid, it can inhibit cholic acid synthesis and is useful in the treatment of primary biliary cirrhosis and nonalcoholic fatty liver disease.

Oberbic acid is developed by the US Intercept Pharmaceutical Company, and it is the first drug in 20 years developed for the treatment of cholestatic liver disease.The study was applied to patients who did not adequately respond to or cannot tolerant the old standard treatment——ursodeoxycholic acid. In a phase III, placebo-controlled trial, oberbetate (OCA) increased the levels of two biomarkers associated with a reduced risk of liver transplantation. The composite endpoint of clinical studies is a decrease at least 15% in alkaline phosphatase activity and of a serum albuminase activity which is 1.67-fold lower than the normal upper limit, whereas in the normal range of bilirubin, alkaline phosphatase is a biomarker used to indicate the severity of liver disease.

Obeticholic acid is also being tested to treat a more common fatty liver - nonalcoholic steatohepatitis. The Phase II study, which was used to treat this indication, was discontinued prematurely because of its definitive efficacy. EvaluatePharma predicts that the sales of Oberbic acid is expected to reach $ 2,920,000,000 in 2020.

 

 

our service 2USA WAREHOUSE

 

 

 

 

 

company Information

Wuhan W&Z Biotech Co,.Ltd is a high-tech enterprise which focus on the R&D, production, sales and service of biomedical and large health field. It has strong scientific research strength, modern management system and high-quality marketing team.
W&Z, located in Wuhan, the national key science and education base, cooperates with Wuhan University, Huazhong University of Science and Technology and other well-known universities, forming a good R&D and production team. in our R & D team, there are five experts in fields.
W&Z focus on provide CRO and CMO services for customers on one-stop intermediates, APIs and green technology. We have established modern R&d laboratories in Wuhan Optical Valley, have two partner factories in Shandong and Sichuan. Besides supplying standard products with mature technology, we also do customize under customer`s personalized needs.
We will uphold the quality first, service-oriented, integrity-based purpose, committed to provide more and more, better and better services to the global customers.

 

 

Contact us 

William

 

 

 

Business TypeTrading CompanyCountry / RegionHubei, China
Main ProductsNutritional Supplements,herbal extract,API & Intermediates,peptides,nootropicsTotal Employees11 - 50 People
Total Annual RevenueAbove US$100 MillionYear Established2017
Certifications Product Certifications 
Patents Trademarks 
Main MarketsNorth America 30%
Western Europe 20%
South America 10%

Wuhan W&Z Biotech Co,.Ltd is a high-tech enterprise which focus on the R&D, production, sales and service of biomedical and large health field. It has strong scientific research strength, modern management system and high-quality marketing team.
W&Z, located in Wuhan, the national key science and education base, cooperates with Wuhan University, Huazhong University of Science and Technology and other well-known universities, forming a good R&D and production team. in our R & D team, there are five experts in fields.

W&Z focus on provide CRO and CMO services for customers on one-stop intermediates, APIs and green technology. We have established modern R&d laboratories in Wuhan Optical Valley, have two partner factories in Shandong and Sichuan. Besides supplying standard products with mature technology, we also do customize under customer`s personalized needs.
We will uphold the quality first, service-oriented, integrity-based purpose, committed to provide more and more, better and better services to the global customers.

Send your message to us

No need register, just fill in contact info below, we will reply you within 24 hours!